CClinicalTrials.gg
CompletedNCT00444145Updated Mar 29, 2017Results posted

Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?

A Phase 4 interventional study of Prevacid and Esophageal and Laryngeal Biopsies in Larynx Disease and Gastroesophageal Reflux, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Vanderbilt University Medical Center · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to determine if tissue changes are predictor of clinical response to therapy.

The hypothesis is that the patients who have laryngeal signs and symptoms related to acid reflux, will have ultrastructural changes on a laryngeal biopsy which are predictors of response to therapy.

Read the detailed description

Gastroesophageal reflux disease (GERD) has been implicated, in part, as the cause of various laryngeal signs and symptoms (1-7). This is often termed reflux laryngitis, ear, nose, and throat (ENT) reflux, or laryngopharyngeal reflux (LPR). GERD was first described to be a causative agent in developing contact ulcers of the larynx (8), and since this early report other routinely observed laryngeal signs are now attributed to LPR. These include laryngeal edema/erythema, vocal cord granulomas and polyps, posterior cricoid cobblestoning, interarytenoid changes, and subglottic stenosis. In addition, patient symptoms attributed to LPR include hoarseness, sore or burning throat, chronic cough, throat clearing, globus, nocturnal laryngospasm, otalgia, post-nasal drip, and dysphagia.

GERD occurs in 7% - 25% of the population on a daily or monthly basis, respectively (9). It is estimated that up to 10% of patients presenting to ENT physicians do so because of complaints that are thought to be related to LPR (2).

The current management of patients with suspected LPR complaints include either 1. empiric therapy using proton pump inhibitors (PPI's) or 2. Ambulatory 24-hour pH monitoring to test for GERD before beginning treatment. Because of the uncertainty and subjectivity of the ENT laryngeal examination in diagnosing LPR, both algorithms fall short of ideal in treating these patients. In a recent review of the literature, remarkably, up to 50% of patients with laryngoscopic signs suggesting LPR do not respond to aggressive acid suppression and do not have abnormal esophageal acid reflux values on pH testing (10). Yet, in this subset of patients LPR continues to be implicated as the probable etiology of the patient's laryngeal signs and symptoms.

Calabrese, et al. recently looked at the reversibility of GERD related ultrastructural alterations in the esophagus using a PPI. Lower esophageal biopsies were analyzed with electron microscopy (EM) for ultrastructural alterations attributed to GERD; that is, dilation of intracellular spaces. Patients were then treated with a PPI and re-biopsied for analysis of any changes of healing that may have occurred in these ultrastructural alterations. Not surprisingly, the ultrastructural alterations showed complete recovery (reduction of dilated intracellular spaces) after treatment with a PPI. Additionally resolution of patient's symptoms coincided with recovery of ultrastructural alterations (11). No such biopsies looking for LPR related changes in the larynx have ever been performed in human subjects. Our initial study which is also submitted for review will provide data on the prevalence of biopsy findings in controls, GERD and LPR patients. Subsequent to this prevalence study, the importance of these findings will be assessed based to determine if these findings will predict response to acid suppressive therapy.

In sum, LPR is an extremely subjective diagnosis, in which nearly half of all patients do not have an abnormal 24hr pH study, nor do they respond to the standard GERD therapy of acid suppression. Finding an alternative objective criterion for GERD induced laryngitis would be an important clinical discovery. To date, there are no data on microscopic changes in the larynx of patients suspected of having LPR. The most important question which this protocol will address is if laryngeal findings specifically by either routine microscopy or electron microscopy would predict response to PPI therapy. This would then result in being able to identify GERD related laryngitis from non-GERD related causes.

02

Conditions studied

  • Larynx Disease
  • Gastroesophageal Reflux
03

In context

Gastroesophageal Reflux

1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.

This study's enrollment of 38 is below the median of 72 across 712 interventional studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 824 studies on the registry; 164 are open to participants now.

Of its 122 completed or terminated interventional studies of FDA-regulated products, 91 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

GERD

  • Documented erosive esophagitis:

    • Patients will be newly diagnosed with esophageal erosion at initial visit via EGD
    • Patients with non-erosive esophagitis who have been responsive to PPI

LPR

  • Diagnosed via Head \& Neck Institute endoscopists:

    • pts with chronic (> 3-months) history of hoarseness, throat clearing, sore- or burning throat and globus
    • Documentation of LPR using Larynx/Pharynx exam.

This group is commonly evaluated at the Vanderbilt Voice Center.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18yrs
  • Pregnancy
  • Patients with contra-indications for EGD
  • Patients on corticosteroids
  • Active smokers
  • Patients with a history of regular (> 2 /day) alcohol use.
  • Use of antacid (PPI, H2RB) within last 30 days
  • Use of any/all medications affecting gastrointestinal motility
  • Known history of: Barrett's esophagus, Peptic stricture, Pyloric stenosis, Gastric resection
  • Patients unable to give informed consent
  • Patients unable to comply with follow-up
  • Patients with known contraindication to lansoprazole.
  • Contraindications to biopsy: Taking anticoagulants other than aspirin (Coumadin, Plavix) or allergic to the local anesthetics.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Patients with documented GERD or laryngopharyngeal reflux

    Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.

    Drug: Prevacid · Procedure: Esophageal and Laryngeal Biopsies

Interventions

  • DrugPrevacid

    30 mg bid for 3 months

    Also known as: lansoprazole

  • ProcedureEsophageal and Laryngeal Biopsies

    repeat egd with biopsy after Prevacid 30 mg bid for 3 months

    Also known as: esophagogastroduodenoscopy

06

What researchers measure

Primary outcomes

  1. Number of Patients With Dilation of Intracellular Spaces 3 Months After Therapy

    Dilation of inter cellular spaces (the space within the cell) is reported to be an early morphological (structure and form) marker in gastro-oesophageal reflux. Using electron microscopy, the distance between epithelial cells is quantified.

    Time frame: 3 months

07

Results

Posted Mar 29, 2017

Participant flow

Participant flow — Overall Study
MilestonePatients Receiving Prevacid
Started38
Completed19
Not completed19
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up1
Withdrew: Non-compliant11
Withdrew: Screen failures5

Outcome measures

PrimaryNumber of Patients With Dilation of Intracellular Spaces 3 Months After Therapy

Dilation of inter cellular spaces (the space within the cell) is reported to be an early morphological (structure and form) marker in gastro-oesophageal reflux. Using electron microscopy, the distance between epithelial cells is quantified.

Time frame:
3 months
Reported as:
Number · participants
Number of Patients With Dilation of Intracellular Spaces 3 Months After Therapy
participantsPatients Receiving Prevacid
Number of Patients With Dilation of Intracellular Spaces 3 Months After Therapy0

Adverse events

Collected over 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Receiving Prevacid—0/19 (0%)0/19 (0%)

Baseline characteristics

Patients diagnosed with GERD as evidenced by erosive esophagitis and patients diagnosed with laryngopharyngeal reflux (LPR)

Age, Categorical
Age, Categorical(Participants)Patients Receiving Prevacid
<=18 years0
Between 18 and 65 years38
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Patients Receiving Prevacid
Female24
Male14
Region of Enrollment
Region of Enrollment(participants)Patients Receiving Prevacid
United States38
08

Study locations

1 site
  • Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410
    Nashville, Tennessee 37232-5280, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00444145
Lead sponsor
Vanderbilt University Medical Center
Responsible party
Michael Vaezi (Principal Investigator, Vanderbilt University Medical Center) — Principal investigator
First posted
Mar 7, 2007
Start date
Mar 2007
Primary completion
Mar 2009
Completion
Dec 2009
Results posted
Mar 29, 2017
Last update
Mar 29, 2017

Study contacts

Michael F Vaezi, MD,PhD
principal investigator · Vanderbilt University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion